Axovant Sciences Ltd. (AXON) Stock Rating Reaffirmed by Robert W. Baird
Axovant Sciences Ltd. (NYSE:AXON)‘s stock had its “outperform” rating restated by equities research analysts at Robert W. Baird in a note issued to investors on Friday. They currently have a $29.00 target price on the stock. Robert W. Baird’s price target indicates a potential upside of 104.37% from the company’s current price.
Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating on shares of Axovant Sciences in a research note on Wednesday, August 17th. Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Monday, August 8th. Jefferies Group reissued a “buy” rating and issued a $31.00 target price on shares of Axovant Sciences in a research note on Monday, September 26th. Evercore ISI reissued a “buy” rating and issued a $29.00 target price on shares of Axovant Sciences in a research note on Friday, September 23rd. Finally, JMP Securities reissued a “buy” rating on shares of Axovant Sciences in a research note on Tuesday, November 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Axovant Sciences presently has an average rating of “Buy” and a consensus price target of $26.33.
Axovant Sciences (NYSE:AXON) traded up 0.50% on Friday, hitting $14.19. The stock had a trading volume of 92,892 shares. Axovant Sciences has a 1-year low of $8.86 and a 1-year high of $21.30. The company’s market cap is $1.41 billion. The stock has a 50 day moving average price of $13.09 and a 200 day moving average price of $13.79.
TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2016/11/25/axovant-sciences-ltd-axon-stock-rating-reaffirmed-by-robert-w-baird.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN increased its position in Axovant Sciences by 1.5% in the third quarter. Wells Fargo & Company MN now owns 8,130 shares of the company’s stock worth $113,000 after buying an additional 117 shares during the period. SG Americas Securities LLC purchased a new position in Axovant Sciences during the third quarter worth $124,000. GSA Capital Partners LLP purchased a new position in Axovant Sciences during the second quarter worth $128,000. Royal Bank of Canada increased its position in Axovant Sciences by 467.6% in the second quarter. Royal Bank of Canada now owns 10,500 shares of the company’s stock worth $135,000 after buying an additional 8,650 shares during the period. Finally, Princeton Capital Management Inc. purchased a new position in Axovant Sciences during the third quarter worth $145,000. Hedge funds and other institutional investors own 28.46% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.